Takeda has been present in Italy for more than 30 years, with Headquarters in Rome and almost 400 employees.
Confident in our expertise in specialty and primary care, we are among the top 20 pharma companies in the country, and collaborate with HCPs and Institutions to guarantee the access of our innovative drugs for patients.
Takeda has a portfolio of more than 700 products in five therapeutic areas: oncology, gastroenterology, cardiovascular & metabolic, central nervous system (CNS) and vaccines. In Italy the portfolio includes products for prostate and breast cancer, osteosarcoma, relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL), ulcerative colitis and Chron Disease, diabetes, hypertension, endometriosis, homeostasis, esophagitis and peptic ulcers.
Takeda is launching a pipeline of new innovative speciality medicines that will drive growth in areas of high unmet medical need for the benefit of patients and their families.